文献速递流行病学与生物统计临床试验与 GCP

肯尼亚和乌干达农村地区HIV高风险人群启动暴露前预防后的HIV发病率:一项基于人群的研究

HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
PubMed 文献 · PLoS Med · 2021-02-09

在肯尼亚和乌干达农村16个社区开展基于人群的PrEP研究,对HIV高风险者提供快速启动和灵活服务。PrEP启动者HIV发病率为0.35/100人年,较匹配历史对照降低74%(aIRR 0.26,95%CI 0.09-0.75;p=0.013),女性降低76%显著,男性降低40%不显著。

要点

  • PrEP启动者HIV发病率较匹配对照降低74%,女性显著降低76%。
  • 男性PrEP启动者HIV发病率降低40%但未达统计学显著。
  • 25例PrEP后感染HIV者中96%启动ART,95%获病毒抑制。

核心结论

  • 基于人群提供PrEP并快速启动和灵活服务,与匹配历史对照相比,PrEP启动者HIV发病率降低74%。
  • 女性PrEP启动者HIV发病率显著降低76%,男性降低40%但不显著。

研究设计与样本

  • 在肯尼亚和乌干达农村16个社区开展基于人群的PrEP研究(SEARCH研究,NCT01864603)。
  • 对≥15岁人群进行HIV检测,为高风险者提供PrEP,随访至144周。
  • 采用泊松回归比较PrEP启动者与倾向评分匹配的历史对照(PrEP可及前一年)的HIV发病率。

主要发现

  • 74,541名HIV阴性者中15,632人(21%)评估为高风险,5,447人(35%)启动PrEP(49%女性;29%为15-24岁;19%为血清不一致伴侣)。
  • PrEP启动者随访7,150人年,HIV发病率为0.35/100人年(95%CI 0.22-0.49)。
  • 匹配对照HIV发病率为0.92/100人年(95%CI 0.49-1.41),aIRR 0.26(95%CI 0.09-0.75;p=0.013)。
  • 女性aIRR 0.24(95%CI 0.07-0.79;p=0.019);男性aIRR 0.60(95%CI 0.12-3.05;p=0.54)。
  • 25例PrEP后感染HIV者中24例(96%)启动ART,19例有ART后HIV RNA者中18例(95%)<1,000 c/ml。

关键数值与推荐

  • 高风险定义基于血清不一致伴侣、机器学习风险评分或自我识别的HIV风险。
  • PrEP启动者79%至少一次随访,61%至少一次自报服药依从。
  • 病毒抑制定义为HIV RNA<1,000 c/ml(基于可用检测方法)。

临床怎么用

  • 在广泛流行地区,结合普遍HIV检测,为高风险者提供快速启动和灵活服务的PrEP可显著降低HIV发病率。
  • 女性从PrEP中获益显著,男性需进一步研究以确认效果。
  • PrEP后仍感染HIV者应尽快启动ART并监测病毒抑制和耐药。

局限性

  • 缺乏同期对照来评估无PrEP时的HIV发病率。
  • 未存档血浆样本以评估基线急性感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral pre-exposure prophylaxis (PrEP) is highly effective for HIV prevention, but data are limited on HIV incidence among PrEP users in generalized epidemic settings, particularly outside of selected risk groups. We performed a population-based PrEP study in rural Kenya and Uganda and sought to evaluate both changes in HIV incidence and clinical and virologic outcomes following seroconversion on PrEP. METHODS AND FINDINGS: During population-level HIV testing of individuals ≥15 years in 16 communities in the Sustainable East Africa Research in Community Health (SEARCH) study (NCT01864603), we offered universal access to PrEP with enhanced counseling for persons at elevated HIV risk (based on serodifferent partnership, machine learning-based risk score, or self-identified HIV risk). We offered rapid or same-day PrEP initiation and flexible service delivery with follow-up visits at facilities or community-based sites at 4, 12, and every 12 weeks up to week 144. Among participants with incident HIV infection after PrEP initiation, we offered same-day antiretroviral therapy (ART) initiation and analyzed HIV RNA, tenofovir hair concentrations, drug resistance, and viral suppression (<1,000 c/ml based on available assays) after ART start. Using Poisson regression with cluster-robust standard errors, we compared HIV incidence among PrEP initiators to incidence among propensity score-matched recent historical controls (from the year before PrEP availability) in 8 of the 16 communities, adjusted for risk group. Among 74,541 individuals who tested negative for HIV, 15,632/74,541 (21%) were assessed to be at elevated HIV risk; 5,447/15,632 (35%) initiated PrEP (49% female; 29% 15-24 years; 19% in serodifferent partnerships), of whom 79% engaged in ≥1 follow-up visit and 61% self-reported PrEP adherence at ≥1 visit. Over 7,150 person-years of follow-up, HIV incidence was 0.35 per 100 person-years (95% confidence interval [CI] 0.22-0.49) among PrEP initiators. Among matched controls, HIV incidence was 0.92 per 100 person-years (95% CI 0.49-1.41), corresponding to 74% lower incidence among PrEP initiators compared to matched controls (adjusted incidence rate ratio [aIRR] 0.26, 95% CI 0.09-0.75; p = 0.013). Among women, HIV incidence was 76% lower among PrEP initiators versus matched controls (aIRR 0.24, 95% CI 0.07-0.79; p = 0.019); among men, HIV incidence was 40% lower, but not significantly so (aIRR 0.60, 95% CI 0.12-3.05; p = 0.54). Of 25 participants with incident HIV infection (68% women), 7/25 (28%) reported taking PrEP ≤30 days before HIV diagnosis, and 24/25 (96%) started ART. Of those with repeat HIV RNA after ART start, 18/19 (95%) had <1,000 c/ml. One participant with viral non-suppression was found to have transmitted viral resistance, as well as emtricitabine resistance possibly related to PrEP use. Limitations include the lack of contemporaneous controls to assess HIV incidence without PrEP and that plasma samples were not archived to assess for baseline acute infection. CONCLUSIONS: Population-level offer of PrEP with rapid start and flexible service delivery was associated with 74% lower HIV incidence among PrEP initiators compared to matched recent controls prior to PrEP availability. HIV infections were significantly lower among women who started PrEP. Universal HIV testing with linkage to treatment and prevention, including PrEP, is a promising approach to accelerate reductions in new infections in generalized epidemic settings. TRIAL REGISTRATION: ClinicalTrials.gov NCT01864603.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Koss CA, Havlir DV, Ayieko J, et al. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. PLoS Med. 2021. PMID: 33561143. doi:10.1371/journal.pmed.1003492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。